Can arginine and glutamine soothe radiation mouth pain?
NCT ID NCT07020754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether mouth rinses containing the amino acids arginine or glutamine could reduce the severity of painful mouth sores caused by radiation therapy in head and neck cancer patients. 69 participants swished and swallowed these supplements three times daily during weeks 2 to 7 of their radiation treatment. Researchers measured inflammation markers, pain levels, and quality of life to see if either supplement helped more than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- L-arginine and L-glutamine oral suspensions
- What this could lead to
- If effective, these amino acid mouth rinses could offer a simple, low-cost way to reduce pain and speed healing of radiation-induced mouth sores.
- What could go wrong
- This is a small Phase 2 trial with only 69 participants, so results may not apply to everyone. The supplements may not outperform the placebo, and any benefit might be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
84 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 20 and 70 years Diagnosed with head and neck cancer (HNC) and undergoing radiotherapy (RT) Development of oral mucositis during the 2nd to 3rd week of RT Receiving a minimum radiation dose of 50 Gy to the oral cavity Undergoing intensity-modulated radiotherapy (IMRT) with three-dimensional conformal techniques after complete tumor resection Ability and willingness to provide informed consent Able to comply with study procedures and follow-up assessments Exclusion Criteria: * History of prior radiotherapy Diagnosed with diabetes mellitus Presence of salivary gland tumors Renal or hepatic insufficiency Sepsis or any active systemic infection Distant metastases Any condition that may interfere with oral sample collection or affect EGF levels (e.g., autoimmune oral disease)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Dentistry, Future University in Egypt
Cairo, Cairo Governorate, 10226, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental pill HG146 put to the test against rare head and neck cancer
- Can a dental assistant keep cancer Patients' mouths healthier during radiation?
- Why do Non-Smokers get head and neck cancer? scientists probe tumor DNA
- Re-irradiation plus cetuximab targets head and neck tumors that return
- Sharper tumor maps: PET scans could tighten radiation beams
- Mouth device aims to keep Sore-Relief rinses where They're needed